Compare RVPH & BIDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVPH | BIDU |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 40.9B |
| IPO Year | N/A | 2005 |
| Metric | RVPH | BIDU |
|---|---|---|
| Price | $0.31 | $124.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $3.33 | ★ $144.23 |
| AVG Volume (30 Days) | ★ 7.9M | 2.3M |
| Earning Date | 11-13-2025 | 11-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.25 |
| Revenue | N/A | ★ $18,325,514,127.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.78 |
| P/E Ratio | ★ N/A | $37.98 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $74.71 |
| 52 Week High | $2.17 | $149.51 |
| Indicator | RVPH | BIDU |
|---|---|---|
| Relative Strength Index (RSI) | 29.72 | 54.26 |
| Support Level | $0.25 | $121.80 |
| Resistance Level | $0.63 | $125.37 |
| Average True Range (ATR) | 0.07 | 2.73 |
| MACD | -0.04 | 0.25 |
| Stochastic Oscillator | 11.40 | 50.70 |
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 70% of core revenue from online marketing services from its search engine in 2024. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.